Study Evaluating LXR-623 in Healthy Subjects

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Inclusion:

• Healthy, men or women, aged 19-50 years

Exlcusion:

• Use of any investigational or prescription drug within 30 days before study start
• Any clinically imprtant medical disease or abnormal laboratory test results